GET DAILY SIGNALSWhy Is Foghorn Therapeutics (FHTX) Stock Down -47.34% Today?
Key Takeaways
- Shares plunged roughly 47% after Foghorn Therapeutics (FHTX) and Eli Lilly (LLY) mutually agreed to discontinue their lead oncology program.
- The companies halted development of FHD-909, a SMARCA2 inhibitor, after Phase 1 data showed favorable safety but insufficient efficacy to justify advancement.
- A second collaborative program — the selective SMARCA2 degrader — was also dropped, effectively ending the partnership.
- Foghorn announced plans to cut about 40% of its workforce and refocus on wholly owned pipeline assets, extending its cash runway into the second half of 2029.
- The selloff pushed the stock toward all-time lows and marked its steepest single-day decline on record.
Opening Summary
Shares of Foghorn Therapeutics Inc. (FHTX), a clinical-stage biopharmaceutical company focused on the chromatin regulatory system, collapsed more than 47% on Thursday. The stock fell from a prior close of $3.57 to around $1.88, a decline of approximately 47.34%. The move came after the company disclosed that it and its partner Eli Lilly (LLY) had agreed to stop developing the experimental cancer drug FHD-909, with the two firms also ending a second joint program and confirming no further collaboration is planned. In response, Foghorn unveiled a restructuring that will eliminate roughly 40% of its workforce.
End of the Lilly Partnership
The primary catalyst was the collapse of Foghorn's flagship collaboration with Eli Lilly. The two companies determined that FHD-909, a first-in-class oral small molecule designed to selectively inhibit the SMARCA2 protein, would not advance beyond its Phase 1 dose-escalation study. While the drug demonstrated a favorable safety profile and achieved drug exposures that exceeded preclinical targets, management said the efficacy was not strong enough to support continued development.
Chief Executive Adrian Gottschalk explained that the synthetic-lethality biology underlying the SMARCA2/4 relationship did not translate into the level of clinical response required to advance the program. The companies also dropped a separate program targeting SMARCA2 degradation, and Foghorn said it does not expect any additional joint activities with Lilly going forward.
The partnership, established in December 2021, had been a cornerstone of investor sentiment. Under the original deal, Foghorn received $300 million upfront and was eligible for up to $1.3 billion in milestone payments, while Lilly made an $80 million equity investment priced at $20 per share — a level far above where shares trade today.
Workforce Reduction and Strategic Reset
Beyond the pipeline setback, Foghorn announced a sweeping restructuring that compounds the negative market reaction. The company plans to cut approximately 40% of its headcount and redirect resources toward wholly owned programs, including its selective EP300 degrader, a selective CBP degrader, and an oral immunology and inflammation program.
Management framed the cost cuts as a cash-preservation measure, projecting that the restructuring will extend the company's cash runway into the second half of 2029. Foghorn ended June with $257.8 million in cash, cash equivalents, and marketable securities. While the extended runway reduces near-term financing risk, the loss of the Lilly collaboration removes a major source of validation and future milestone funding.
Market Context and Trading Activity
Trading in FHTX was temporarily halted ahead of the announcement. Once the halt was lifted, selling pressure intensified rapidly, with volume running well above the stock's typical daily average. The move sent shares toward all-time lows and put the stock on track for its largest single-day percentage loss in its history.
The decline was company-specific rather than a reflection of broader biotech weakness. For Eli Lilly, the market reaction was muted, with the pharma giant's shares moving only modestly lower — an insignificant move for a company of its scale. Foghorn's collapse underscores how concentrated the downside risk can be for small-cap biotechs whose valuation is tied to a single partnered program.
What Comes Next for FHTX
Foghorn now enters a period of transition. With the Lilly collaboration terminated, the company will rely on its internal pipeline and a leaner organization to generate value. Investors will be watching for clinical entries and data readouts from the EP300 degrader, CBP degrader, and immunology/inflammation programs, as management works to restore confidence in the platform.
The company's extended cash runway into late 2029 removes some near-term overhang, but the path forward carries meaningful risk. The newly prioritized programs are still early-stage, and the disappointing FHD-909 outcome raises questions about the translatability of the underlying biology. Upcoming earnings and corporate updates will be closely scrutinized for signs of pipeline progress and disciplined capital allocation.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are performing strongly under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the top performers are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of approaches to explore. To see which automated strategies are leading right now, visit the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FHTX's RSI Oscillator climbs out of oversold territory
The RSI Indicator for FHTX moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on FHTX as a result. In 71 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for FHTX just turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 30 of 35 cases over the following month. The odds of a continued upward trend are 86%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 58 cases where FHTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.539) is normal, around the industry mean (2.904). P/E Ratio (-2.121) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. FHTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement